Crossmark

Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)—a phase III, prospective, multicentre, randomized study: design and methods

Crossref DOI link: https://doi.org/10.1038/s41433-022-02154-8

Published Online: 2022-07-05

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Coulibaly, Leonard M.

Sacu, Stefan

Fuchs, Philipp

Bogunovic, Hrvoje https://orcid.org/0000-0002-9168-0894
Faustmann, Georg

Unterrainer, Christian

Reiter, Gregor S. https://orcid.org/0000-0001-7661-4015
Schmidt-Erfurth, Ursula https://orcid.org/0000-0002-7788-7311
License Information

Text and Data Mining valid from 2022-07-05

Version of Record valid from 2022-07-05
More Information

Article History

Received: 20 December 2021

Revised: 15 June 2022

Accepted: 16 June 2022

First Online: 5 July 2022

Competing interests

: US-E is a scientific consultant for Genentech, Heidelberg Engineering, Kodiak, Novartis, RetInSight and Roche. GSR received research funds outside this work from RetInSight. HB reported receiving financial research support outside this work from Apellis Pharmaceuticals, Inc, and Heidelberg Engineering GmbH, as well as speaker fees from Bayer, Roche, and Apellis. The other authors have nothing to declare.

: Ethics approval was obtained from the ethical commission of the Medical University Vienna on 30.08.2019.

Document is current

Any future updates will be listed below